Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Clinical trial NCT06329973 · RECRUITING
Trial details
- NCT number
- NCT06329973
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-28
- Primary completion
- 2026-06-28
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.